Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 76.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 23,591 shares of the biopharmaceutical company’s stock after purchasing an additional 10,213 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $24,800,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. Cetera Investment Advisers raised its position in shares of Regeneron Pharmaceuticals by 156.8% during the 1st quarter. Cetera Investment Advisers now owns 9,753 shares of the biopharmaceutical company’s stock worth $9,387,000 after buying an additional 5,955 shares in the last quarter. Park Avenue Securities LLC lifted its position in Regeneron Pharmaceuticals by 5.0% in the second quarter. Park Avenue Securities LLC now owns 1,755 shares of the biopharmaceutical company’s stock worth $1,845,000 after purchasing an additional 84 shares during the period. CWM LLC boosted its stake in Regeneron Pharmaceuticals by 2.2% during the 2nd quarter. CWM LLC now owns 2,247 shares of the biopharmaceutical company’s stock valued at $2,361,000 after purchasing an additional 49 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 23.5% during the 2nd quarter. Valeo Financial Advisors LLC now owns 1,105 shares of the biopharmaceutical company’s stock valued at $1,161,000 after purchasing an additional 210 shares during the period. Finally, U.S. Capital Wealth Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.2% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 2,175 shares of the biopharmaceutical company’s stock worth $2,286,000 after buying an additional 67 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

REGN has been the topic of a number of research analyst reports. Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Stock Down 1.7 %

Regeneron Pharmaceuticals stock opened at $749.57 on Wednesday. The firm’s 50 day moving average price is $893.12 and its two-hundred day moving average price is $1,016.56. The firm has a market cap of $82.37 billion, a PE ratio of 18.55, a P/E/G ratio of 2.94 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.